The passage of the MAT Act removed the requirement for DEA-licensed healthcare providers to undergo additional training to obtain an X-Waiver. This legislation also removed limits on the number of patients that prescribers could treat at a time for opioid use disorder.
Since this announcement, the U.S. Drug Enforcement Administration (DEA), the Substance Abuse and Mental Health Services Administration (SAMHSA), The New York State Department of Health (NYSDOH), and The New York State Office of Addiction Services and Supports (OASAS) have released updated information on the impact of this legislation.
DEA Announcement
- A DATA Waiver registration is no longer required to prescribe buprenorphine for opioid use disorder (OUD)
- All prescriptions for buprenorphine require a standard DEA registration number
- DATA Waiver registration numbers are no longer required for a buprenorphine prescription
- There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine
- Local laws or legislations may still be applicable that impact this legislation
- New training requirements go into effect June 21, 2023
SAMHSA Updates
- Removes the federal requirement for practitioners to submit a Notice of Intent, which previously served as an X-Waiver application
- 275 Annual Reports are no longer required nor accepted by SAMHSA
- All health care providers with a current DEA registration (including Schedule III authority) may now prescribe buprenorphine for OUD
This legislation will reduce barriers for patients and providers in addressing opioid use disorder across the country. Thank you to our local, regional, and national partners for moving this important bill forward.
Have questions? Contact the MATTERS Team!
